Company Overview and News
20h seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
CAT UVVZP RGS SIRI TJX SNCR AEP NOK CAG FSLR KIM PFSI SNAP RUBI ABX MO MMM MRCY GILD MCFT ETR ABRW BABA GSHD DVMT JNJ VZ MSFT LMT QTT PRNB SCG TM DOCU AMD QNST BAC SMAR OKE INTC BIDU PRFT CREE UN UVV LLY GSK JPM FVCB NUAN WRK ARRY AX PCSB FCX ZPTAF CFIN AMZN CIWV CDAY TWTR OMC CELG GSK AGNC LASR MAC YI BAC AAL QURE NBEV AUDVF CTSH CMG GOOGL BA PFE KRNY DRE PF SGY COP SPVEF GM ALZH ORCL MCD BMY F ABX CMCSA TECH MSTR SPVVF CFG V LAIX T MRK SNE
2018-10-19 reuters - 1
(Reuters) - SolarWinds Corp’s shares SWI.N rose as much as 3.2 percent in their downsized U.S. market debut on Friday, giving the enterprise software maker a market value of about $4.80 billion.
IBM LMT DVMT NTCT SWI MS
Ladies and gentlemen, thank you for standing by. I'm Stuart, your chorus call operator. Welcome, and thank you for joining the Software AG Release Q3 Results 2018 Conference Call. [Operation Instructions]
SWDAF DVMT KORS MS DTEGF DTEGY
Dell Technologies Inc will ask holders of "tracking stock" tied to its software company VMware Inc to vote on its US$21.7 billion cash-and-stock offer to buy it back from them on Dec. 11, according to people familiar with the matter.
(Reuters) - Dell Technologies Inc will ask holders of “tracking stock” tied to its software company VMware Inc to vote on its $21.7 billion cash-and-stock offer to buy it back from them on Dec. 11, according to people familiar with the matter.
An escalating battle between the U.S. and China for supremacy in semiconductor technology is playing out in federal court between Chinese telecommunications giant Huawei Technologies Co. and a Silicon Valley startup backed by Microsoft Corp. and Dell Technologies Inc.
New Delhi: VMware Inc, a leading innovator in enterprise software and a listed unit of Dell Technologies Inc, plans to invest $2 billion in VMware-specific efforts in India between now and 2023 as part of the company’s overall global investment strategy.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET